IOP-independent treatment for neurodegeneration in glaucoma using optimized ROS-scavenging microparticles for sustained release of erythropoietin

Erythropoietin-loaded PPSES antioxidant microparticles preserve neurons in mouse and non-human primate glaucoma models by suppressing oxidative stress and optic nerve degeneration.

• Why it matters: IOP-lowering fails for many patients, and glaucomatous neurodegeneration is linked to increased reactive oxygen species, creating a need for IOP-independent antioxidant strategies.
• What they did: The study optimized size-controlled, stabilized PPSES microparticles for sustained EPO release, leveraging PPSES ROS scavenging and EPO’s NRF2-mediated antioxidant gene activation.
• The result: The lead EPO-MP formulation suppresses oxidative stress and optic nerve degeneration in both mouse and non-human primate models, supporting translational long-term glaucoma management independent of IOP.

AI summary of the abstract · may contain errors · not medical advice · read the paper.